Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$32.01 USD

32.01
1,959,949

+0.44 (1.39%)

Updated May 31, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe

by Zacks Equity Research

Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive breast cancer patients. It continues to evaluate Nerlynx in other types of cancer and indications.

Novartis (NVS) Plans to Spin Off Generics Business Sandoz

by Zacks Equity Research

Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.

AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why

by Zacks Equity Research

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Roche's (RHHBY) sBLA For Polivy Combo Accepted by FDA

by Zacks Equity Research

Roche's (RHHBY) sBLA seeking approval for the use of Polivy in combination with R-CHP for previously untreated diffuse large B-cell lymphoma in adults has been accepted in the United States.

Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

Halozyme (HALO) Q2 Earnings and Sales Beat, Ups '22 Outlook

by Zacks Equity Research

Halozyme's (HALO) second-quarter earnings and sales beat estimates. Following the completion of the acquisition of Antares Pharma, the company raises its financial guidance for 2022.

The Zacks Analyst Blog Highlights Roche Holding, Adobe, McDonald, Deere & Co and BP p.l.c

by Zacks Equity Research

Roche Holding, Adobe, McDonald, Deere & Co and BP p.l.c are part of Zacks top Analyst Blog.

Sheraz Mian headshot

Q2 Earnings Scorecard and Analyst Reports for Roche, Adobe & McDonald's

by Sheraz Mian

Today's Research Daily features update on the Q2 earnings season and new research reports on Roche (RHHBY), Adobe (ADBE), and McDonald's (MCD).

Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus

by Zacks Equity Research

Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.

Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat

by Zacks Equity Research

Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.

Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx

by Zacks Equity Research

Amgen (AMGN) beats Q2 estimates for earnings and sales. It offers to buy ChemoCentryx (CCXI) for $3.7 billion.

Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.

Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent

by Zacks Equity Research

Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.

Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark

by Zacks Equity Research

Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.

ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.

    Seagen's (SGEN) Earnings & Revenues Surpass Estimates in Q2

    by Zacks Equity Research

    Seagen (SGEN) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates.

    Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints

    by Zacks Equity Research

    Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.

    AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use

    by Zacks Equity Research

    AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.

    Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance

    by Zacks Equity Research

    Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.

    Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down

    by Zacks Equity Research

    Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.

    Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates

    by Zacks Equity Research

    Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.

    Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?

    by Zacks Equity Research

    Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.

    Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD

    by Zacks Equity Research

    Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.

    BAYRY vs. RHHBY: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    BAYRY vs. RHHBY: Which Stock Is the Better Value Option?

    Ionis (IONS) Partner to Begin Phase III Study on Kidney Drug

    by Zacks Equity Research

    Ionis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the treatment of IgAN after announcing positive data from a phase II study.